Addex Therapeutics' Upcoming Earnings Call: A Critical Moment for Neurological Drug Development

Geneva, Monday, 22 June 2026.
On June 25, 2026, Addex Therapeutics will reveal its Q1 2026 financial results and clinical pipeline updates, spotlighting dipraglurant—a late-stage drug candidate for levodopa-induced dyskinesia. With biotech funding under pressure post-pandemic, this call could redefine investor confidence in Addex’s $1.2B market-cap strategy amid fierce competition in neurological therapies.